API-Anti Epilepsy
brivaracetam
CAS: 357336-20-0
Molecular Formula: C33H41N3O10S2
API-Anti Epilepsy - Names and Identifiers
API-Anti Epilepsy - Physico-chemical Properties
| Molecular Formula | C33H41N3O10S2 |
| Molar Mass | 703.83 |
| Density | 1.062 |
| Melting Point | 76.38° |
| Boling Point | 409.3±28.0 °C(Predicted) |
| Specific Rotation(α) | D25 -60.57° (c = 1 in methanol) |
| Solubility | DMSO (Slightly), Methanol (Slightly) |
| Appearance | Solid |
| Color | White to Off-White |
| pKa | 15.74±0.50(Predicted) |
| Storage Condition | Refrigerator |
| Use | Application bovaracetam is a new generation antiepileptic drug approved by the FDA for the treatment of partial seizures in patients with epilepsy aged 16 years and older, and can be used in laboratory research, and in pharmaceutical development processes. |
API-Anti Epilepsy - Upstream Downstream Industry
| Downstream Products | Brivaracetam (alfaR, 4R)-Isomer |
API-Anti Epilepsy - Uses and synthesis methods
overview
The drug was approved by the US Food and Drug Administration (FDA) on February 19 and is mainly used for the adjuvant treatment of partial seizures in patients aged 16 years and above. Compared with the previous generation drug levetiracetam, the drug has a similar chemical structure and mechanism of action. It is the first anti-epileptic drug approved by the FDA for the treatment of partial seizures since 2013.
indications
Bouacetam (brivaracetam) is a highly selective and affinity synaptic vesicle protein 2A ligand approved for the treatment of partial seizures in adults and adolescents over 16 years of age, with or without adjuvant therapy for secondary systemic seizures.
main function
Bouacetam has a high affinity and can selectively bind to synaptic vesicle protein 2A(SV2A), which is the site of action of AED levetiracetam. SV2A is located in the presynaptic membrane and participates in mediating the release of neurotransmitters and vesicle circulation to maintain the normal function of synaptic vesicles. The combination of AED and SV2A can reduce the release of excitatory neurotransmitters, and achieve the effect of controlling seizures by regulating the balance of excitatory and inhibitory transmitters in the brain. The affinity of boiracetam is 15-30 times that of levetiracetam, which reduces its dosage by about 10 times.
Last Update：2024-04-09 20:52:54
Supplier List
View History
Downstream Products for API-Anti Epilepsy